title: 17 beta-estradiol stimulates prostacyclin, but not endothelin-1, production in human vascular endothelial cells.
abstract: The exact mechanisms by which estrogens protect against occlusive vascular disorders are not known. One possibility could be an effect on vascular endothelial vasoactive compounds, such as vasodilatory prostacyclin (PGI2) and vasoconstrictory endothelin (ET-1). Here we report on the effect of 17 beta-estradiol on the synthesis of PGI2 and ET-1 in cultured human umbilical vein endothelial cells. These cells were incubated in the absence (control) and presence of 17 beta-estradiol (0.001-1 mumol/L) for 3-24 h with serum (10%) or without serum. The release of PGI2, as assessed by its metabolite 6-keto-prostaglandin F1 alpha, and that of ET-1, were assessed by RIA. 17 beta-Estradiol (0.01-0.1 mumol/L) predissolved in ethanol (final concentration, 0.01%) increased PGI2 production by 26-30% in endothelial cells incubated without serum. This increase in PGI2 production was enhanced up to 66% when 17 beta-estradiol (1 mumol/L) was encapsulated within beta-cyclodextrin. The stimulation of PGI2 production was detectable after 12 h of incubation. The 17 beta-estradiol-induced stimulation of PGI2 production was blocked in dose-dependent manner by antiestrogenic tamoxifen. 17 beta-Estradiol failed to affect the production of PGI2 if the endothelial cells were incubated with serum and had no effect on ET-1 production under any conditions. 17 beta-Estradiol-induced stimulation of vasodilatory and antiaggregatory PGI2 production without a concomitant change in vasoconstrictory ET-1 production may provide one explanation for the ability of estradiol to maintain vascular health and protect against vascular disorders.
authors.affiliation: Department of Obstetrics and Gynecology, University of Helsinki, Finland.
authors.forename: T
authors.initials: T
authors.lastname: Mikkola
authors.forename: P
authors.initials: P
authors.lastname: Turunen
authors.forename: K
authors.initials: K
authors.lastname: Avela
authors.forename: A
authors.initials: A
authors.lastname: Orpana
authors.forename: L
authors.initials: L
authors.lastname: Viinikka
authors.forename: O
authors.initials: O
authors.lastname: Ylikorkala
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D002478:Cells, Cultured; D003505:Cyclodextrins; D004337:Drug Carriers; D016232:Endothelins / Q000096:biosynthesis*; D004730:Endothelium, Vascular / Q000187:drug effects / Q000378:metabolism*; D011464:Epoprostenol / Q000096:biosynthesis*; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology*; D006801:Humans; D013629:Tamoxifen / Q000494:pharmacology; D014471:Umbilical Veins; D047392:beta-Cyclodextrins
chemical_list: D003505:Cyclodextrins; D004337:Drug Carriers; D016232:Endothelins; D047392:beta-Cyclodextrins; D013629:Tamoxifen; D004958:Estradiol; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; C031215:betadex